Clinically Meaningful Improvement in Both PFS Primary Endpoints from PIK3CA WT Cohort of Ph 3 VIKTORIA-1 Trial Announced July 29, 2025
European Commission approves Itovebi for people with ER+ve HER2neg advanced breast cancer with a PIK3CA mutation July 29, 2025
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines including oncology July 29, 2025
CBX-663 nominated for the treatment of a broad range of solid tumor and heme malignancies July 29, 2025
Positive Data from Long-Term Follow-Up Analysis of the Ph 3 AGILE Trial of TIBSOVO® (ivosidenib) in IDH1-mutated AML Announced July 29, 2025
Imfinzi granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and GEJ cancers July 29, 2025
Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma July 29, 2025
Development of CY-101 for Cancers Driven by Dysfunction of Wnt/β-catenin Signalling to be Advanced Under International Nonproprietary Name of Getacatetide July 29, 2025
Dispatch Bio Launches to Deliver Universal Treatment Across Solid Tumors with Novel Immunotherapy Approach July 29, 2025
Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for ADCs July 29, 2025
Xenetic Biosciences Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform July 29, 2025
Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance July 29, 2025
Akari Therapeutics Continues Key Research on its Novel ADC Payload PH1 to Demonstrate its Ability to Target Cancers Fueled by Oncogenic Drivers July 29, 2025
First Patient Dosed in Ph 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors July 29, 2025
First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer July 29, 2025
Complete Response Reported in Heavily Pre-Treated Lymphoma Patient with LP-284 in Ph 1 Trial July 29, 2025
Positive Mid-year Safety and Efficacy Data from Ph 2 Study of Ampligen® (rintatolimod) + Imfinzi Combo for the Treatment of Pancreatic Cancer Reported July 29, 2025
Ph 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent LGIR-NMIBC published in Reviews in Urology July 29, 2025
Positive CHMP Opinion for VORANIGO® (vorasidenib) for the Treatment of Adults and Adolescents with Grade 2 IDH-mutant Diffuse Glioma July 29, 2025
